Trials / Completed
CompletedNCT00616629
Cardiac Electrophysiological Study
A Multi-centre, Double-blind, Randomised, Placebo-controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1305 | Intravenous infusion |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2008-02-15
- Last updated
- 2011-09-22
- Results posted
- 2011-09-22
Locations
13 sites across 4 countries: Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.gov record NCT00616629. Inclusion in this directory is not an endorsement.